6-methyl-2-(phenylethynyl)pyridine and Central-Nervous-System-Diseases

Although multiple metabotropic glutamate (mglu) receptor subtypes were cloned in the early 1990s, progress in the characterization of these receptors has been slow because of difficulties in obtaining subtype-selective ligands. However, in the past few years exciting progress has been made on the mglu(5) receptor subtype following the identification of selective non-amino-acid-like ligands that implicate the mglu(5) receptor as a potentially important therapeutic target, particularly for the treatment of pain and anxiety.

Topics: Allosteric Regulation; Animals; Anxiety; Brain; Central Nervous System Diseases; Depression; Excitatory Amino Acid Antagonists; Humans; Neurons, Afferent; Pain; Parkinson Disease; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate